股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 7, 2025, the latest net value of the fund is 1.5753 yuan, reflecting a decrease of 1.28%. The fund's return over the past month is -2.61%, ranking 4118 out of 4649 in its category. Over the past three months, the return is 4.24%, ranking 1179 out of 4597, and since the beginning of the year, the return is 1.73%, ranking 2415 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University in the United States. She has held various research and fund management positions before becoming the manager of the China Europe Medical Health Mixed Fund [2]

Core Viewpoint - The impact of the U.S. "reciprocal tariffs" on Chinese pharmaceutical companies is limited, with many companies reporting normal operations and minimal effects on their business [1][2][4][7][12]. Group 1: Company Responses - Heng Rui Pharmaceutical reported that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs have a minimal impact on its business [1]. - Han Yu Pharmaceutical stated that it has a diversified market presence across North America, Asia, Europe, and South America, which mitigates risks from single market policy changes [2]. - Bai Yang Pharmaceutical noted that its supply chain is globally diversified, and the impact of tariffs is minimal [3]. - WuXi AppTec acknowledged that tariffs will have some impact but emphasized their optimized supply chain and management practices to minimize effects [4]. - Kangtai Biological confirmed that it has no products exported to the U.S. and is focusing on markets along the Belt and Road [5]. Group 2: Industry Trends - The medical device industry in China is rapidly developing, with companies like Mindray Medical actively seeking alternatives for U.S. imported raw materials [5]. - Companies are increasingly focusing on domestic production and local supply chains to counteract potential tariff impacts [6][8]. - The vaccine industry in China is evolving, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology [8][9]. - The overall sentiment among Chinese pharmaceutical companies is that the current tariff situation presents an opportunity for domestic substitution and innovation [10][12].

Market Overview - The Hang Seng Index rose 1.74% and the Hang Seng Tech Index increased by 3.08% on the first trading day of May [1] - Despite a seemingly positive outlook for US stocks, there was a significant outflow of $8.9 billion from the US stock market, marking the largest outflow since December 2023 [1] - The US Chamber of Commerce urged the Trump administration to implement a tariff exemption mechanism to prevent economic recession and harm to small businesses [1] Trade Relations - The Chinese Ministry of Commerce noted a shift in the US stance regarding tariff negotiations, indicating a willingness to engage in talks [2] - The FTSE China A50 index futures reacted positively, rising over 0.9%, and the offshore RMB appreciated significantly against the USD [2] - New tariff adjustments confirmed that auto parts from Canada and Mexico will be exempt from a 25% tariff starting May 3 [2] Automotive Sector - Xpeng Motors reported a record delivery of over 30,000 vehicles for six consecutive months, with specific models achieving significant sales milestones [3] - Leap Motor's delivery volume for April reached 41,039 units, a 173% year-on-year increase, leading to a stock price increase of over 7% [3] - Xiaomi's automotive division also saw a rise in deliveries, contributing to a stock increase of over 6% [3] Technology Sector - Major US tech companies like Meta, Microsoft, and Apple reported strong earnings, unaffected by tariff issues, and reaffirmed aggressive AI investment plans [4] - The upcoming US non-farm payroll report is anticipated to influence market expectations regarding Federal Reserve interest rate decisions [4] - President Trump's recent sanctions on countries purchasing oil from Iran are viewed as a bargaining chip rather than a definitive policy change [4] Berkshire Hathaway - Berkshire Hathaway's annual shareholder meeting is set to take place, where Warren Buffett will discuss market perspectives and investment strategies, including significant cash reserves [5] Nuclear Energy Development - There is a global surge in the development of small modular reactors (SMRs) driven by climate change initiatives and demand for clean energy [6] - China's advancements in SMR technology are notable, with significant projects like the BEST project aimed at demonstrating fusion energy generation [6] Company Performance - China State Construction International reported a 5.5% year-on-year revenue increase in Q1 2025, with a notable rise in technology-related income [7] - The company’s new contract value decreased by 29.1% year-on-year, but adjusted figures show a strong performance when excluding high baseline effects from previous major projects [8] - The technology segment's revenue contribution increased to 20%, indicating a positive trend in the company's business model and market positioning [8]

Market Overview - The Hong Kong stock market experienced a collective rise during the holiday, with the Hang Seng Index increasing by 1.74%, the Hang Seng China Enterprises Index rising by 1.92%, and the Hang Seng Tech Index climbing by 3.08% [1][2]. Technology Sector - Tech stocks saw significant gains, with Xiaomi Group rising over 6%, Alibaba and JD.com increasing by over 3%, and Tencent up by over 2% [2]. - Notable individual performances included Tencent Holdings at 487.80 HKD (+2.22%), Alibaba at 122.00 HKD (+3.83%), and Xiaomi at 53.10 HKD (+6.31%) [3]. Robotics and AI - Robotics stocks surged, with Horizon Robotics increasing by over 14%, and other companies like Shengye and Jinli Permanent Magnet rising by over 11% and 5%, respectively [4][5]. Healthcare and Biotech - The healthcare outsourcing sector was active, with Kanglong Chemical and WuXi AppTec both rising over 7%, and WuXi Biologics increasing by over 5% [6]. New Energy Vehicles - New energy vehicle companies saw substantial increases, with Leap Motor rising over 7%, Xiaopeng Motors and Xiaomi both up over 6%, and Li Auto and BYD increasing by over 3% [7]. Consumer Goods - Beer stocks performed well, with Hong Kong San Miguel rising over 4%, and Qingdao Beer and Budweiser APAC both increasing by over 2% [8]. - Home appliance stocks also strengthened, with Quan Feng Holdings rising over 7%, and Hisense and Techtronic Industries increasing by over 4% [9]. Gambling Sector - The gambling sector saw broad gains, with Galaxy Entertainment and MGM China both rising over 2% [10]. Restaurant Sector - The restaurant sector faced declines, with Yum China dropping over 7% and other companies like Chaogao and Cafe de Coral decreasing by over 1% [11]. Local Consumption - Local consumption stocks weakened, with Chao Yue Holdings falling over 6% and Chow Tai Fook down over 1% [13]. Stock Performance - Hong Kong Exchanges saw a peak increase of 3.46% during trading, reaching 352.6 HKD, marking a new high since early April [13]. - Standard Chartered Group's stock initially rose over 4% post-earnings but closed up only 0.71% at 113.6 HKD, with a total market value of 269.225 billion HKD [15]. Future Outlook - Huatai Securities noted that the market has largely priced in the impact of tariffs on earnings expectations, with a 1.5% downward adjustment in profit expectations for core offshore Chinese stocks [17].

Financial Performance - In 2024, the company achieved a revenue of CNY 12,275.8 million, representing a year-on-year growth of 6.4%[11] - The profit attributable to the owners of the parent company was CNY 1,793.4 million, reflecting a year-on-year increase of 12.0%[11] - The net cash flow from operating activities was CNY 2,576.7 million, a decrease of 6.4% compared to the previous year[11] - Total revenue for the year ended December 31, 2024, was approximately RMB 12,275.8 million, an increase of about RMB 737.8 million or 6.4% compared to 2023[17] - Profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing an increase of about 12.0% from the previous year[17] - Net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to 2023[17] - The gross profit for 2024 was approximately RMB 4,149.3 million, reflecting a slight increase of 1.3% from 2023[17] - The company achieved operating revenue of 12,275.8 million, a year-on-year increase of 6.4%[36] - The net profit attributable to the parent company was 1,793.4 million, up 12.0% compared to the same period last year[36] Research and Development - The company participated in 781 global innovative drug discovery projects in 2024[12] - The company provided services for 1,066 drug molecules or intermediates, including 782 preclinical projects and 242 clinical I-II phase projects[12] - The company is currently conducting 1,062 clinical trial projects, including 94 phase III clinical trials[12] - In 2024, the company published 42 articles in international academic journals and obtained or submitted 34 domestic and international patents[12] - The company made significant advancements in automation and artificial intelligence technologies, enhancing drug development efficiency[13] - The company continues to strengthen its core competitive advantages in new drug research and development services[13] - The company aims to cultivate more skilled and dynamic talent through various academic platforms and awards to enhance its innovation capabilities[16] - The company is committed to leveraging AI technology for target discovery and drug evaluation, integrating multi-omics data to improve efficiency in drug discovery services[15] - The company is actively exploring AI and machine learning applications in drug discovery and process optimization to enhance R&D efficiency[42][48] - The company has established a comprehensive clinical trial service platform in China and an independent early clinical research center in Maryland, USA, with 96 beds[51] Service Capabilities - The company operates a leading integrated pharmaceutical R&D service platform with 21 R&D centers and production bases across China, the UK, and the US[25] - The laboratory services include drug chemistry, synthesis chemistry, and biological sciences, covering small molecule drugs, oligonucleotides, peptides, and antibody-drug conjugates[28] - The CMC (small molecule CDMO) services support clients in drug development stages, including process development and production for various products[30] - The clinical research services encompass overseas and domestic clinical trials, with a focus on early clinical trials and regulatory submissions[31] - The company has established bioanalytical platforms in China and the US to support global clinical trials for small molecules and biologics[32] - The company aims to enhance its international service capabilities to provide cross-disciplinary and cross-regional solutions for clients[25] - The company is committed to becoming a global leader in multi-therapy drug development services[25] - The company offers large molecule drug discovery and development services, including cell line development and production processes[33] - The company has established a leading integrated pharmaceutical R&D service platform, expanding its capabilities in small molecules, peptides, oligonucleotides, and gene therapy drugs, while maintaining a strong position in drug discovery and early clinical research[83] Environmental and Social Responsibility - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, successfully achieving its annual carbon reduction target[40] - The company was included in the S&P Global "Sustainability Yearbook 2025" and improved its MSCI ESG rating to AA[40] Client Engagement and Market Position - The company served over 3,000 global customers in 2024, with revenue from customers using multiple service segments reaching 9,187.8 million, accounting for 74.8% of total revenue[37] - Revenue from the top 20 global pharmaceutical clients was 2,188.5 million, a year-on-year increase of 26.9%, representing 17.8% of total revenue[37] - The company has attracted over 900 new clients in 2024, with nearly 95% of its revenue coming from a loyal and diverse customer base[98] - The company emphasizes strategic partnerships with specific clients, enhancing its technical capabilities and service quality through shared proprietary knowledge and training[99] Governance and Management - The board consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors, ensuring diverse governance[133] - The board has reviewed its diversity policy on March 26, 2025, and considers the current implementation effective[175] - The board's structure includes three executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced governance approach[171] - The company emphasizes a culture of "employees first, customers at the center," which is integral to its operational strategy[164] - The board will continue to enhance communication with shareholders to improve governance standards and incorporate their reasonable suggestions[168] Financial Strategy and Investments - The company completed the sale of its stake in PROTEOLOGIX, INC. to Johnson & Johnson for approximately USD 102 million, receiving USD 86.195 million after adjustments[74] - The company has committed RMB 280 million as a limited partner in the Yongxin Kangjun Fund, which constitutes a related party transaction under the listing rules[77] - The company has signed a comprehensive strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd., focusing on integrated services for drug discovery, preclinical and clinical development, with an investment totaling RMB 191 million in the AstraZeneca Fund, accounting for 8.46% of the total subscription[76] Risks and Challenges - The company faces risks from fluctuations in the pharmaceutical investment climate and changes in R&D budgets from multinational pharmaceutical companies, which may impact growth expectations[113] - The company has established a strong talent pool but risks losing qualified research personnel to competitors, which could affect service quality[114] - Regulatory compliance is critical, as failure to meet standards could result in operational suspensions or penalties, impacting client relationships[116] - Foreign exchange risks are significant, with a large portion of revenue generated in USD while costs are primarily in RMB, leading to potential volatility[120] Future Outlook - The company aims to enhance its integrated drug R&D service platform, focusing on ADC and peptide services while strengthening its small molecule R&D capabilities[104] - The company plans to expand its customer base in large molecule and cell and gene therapy services, leveraging its existing advantages to improve operational efficiency[104] - The company is committed to a dual-market strategy, enhancing its presence in both domestic and international markets, with a focus on optimizing service platforms and attracting new clients[105] - The company will continue to develop its large molecule and cell gene therapy service platforms, leveraging existing laboratories in the US and UK[108]

Financial Performance - In Q1 2025, the Company reported revenue of RMB 2,671 million, a decrease of 16.0% compared to RMB 3,099 million in Q1 2024 [10] - Net profit for Q1 2025 was RMB 231 million, down 32.5% from RMB 306 million in Q1 2024 [10] - Non-IFRS net profit slightly decreased by 3.1% to RMB 339 million from RMB 349 million in Q1 2024 [10] - Net operating cash flow was RMB 746 million, a decline of 14.4% from RMB 853 million in Q1 2024 [10] Revenue Composition - Revenue from China entities accounted for 88%, while overseas subsidiaries contributed 12% [12] - Laboratory services generated 60% of total revenue, followed by small molecule CDMO services at 22%, and clinical development services at 14% [12] - Revenue from the top 20 pharmaceutical customers grew by 29.1%, while revenue from other customers increased by 14.0% [12] Growth Rates - New purchase orders (POs) achieved over 10% year-on-year growth in Q1 2025 [10] - Revenue from China entities grew by 15.7%, while overseas subsidiaries saw an 18.3% increase [12] - North America revenue increased by 16.8%, and EU revenue grew by 26.6% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024, reflecting a 1.4 percentage point increase [14] - Gross margin for small molecule CDMO services rose to 30.4%, up 2.5 percentage points from 27.9% in Q1 2024 [15] - Clinical development services in China achieved a gross margin of 11.8%, an increase of 2.5 percentage points from 9.3% in Q1 2024 [16] Future Outlook - The Company maintains a revenue growth guidance of 10-15% for 2025 [27] - Despite macroeconomic uncertainties, the Company believes in sustained industry development driven by healthcare demands and technological innovations [27]

Financial Performance - Revenue for Q1 2025 reached RMB 3,099 million, a 16.0% increase from RMB 2,671 million in Q1 2024 [9] - Net profit attributable to shareholders was RMB 306 million, up 32.5% from RMB 231 million in Q1 2024 [9] - Non-IFRS adjusted net profit increased by 3.1% to RMB 349 million from RMB 339 million [9] - Operating cash flow for Q1 2025 was RMB 853 million, a 14.4% increase from RMB 746 million in Q1 2024 [9] Revenue Composition - Revenue from China delivery business grew by 15.7% [11] - Revenue from overseas delivery business increased by 18.3% [11] - Laboratory services contributed 60% to revenue, with clinical research services at 14% and CDMO at 22% [11] - Revenue from top 20 pharmaceutical companies grew by 29.1% [14] Customer Growth - Revenue from North American clients increased by 16.8% [12] - Revenue from European clients rose by 26.6% [12] - Revenue from Chinese clients grew by 13.1% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024 [17] - Gross margin for clinical services increased to 11.8% from 9.3% [19] - Gross margin for large molecule services improved despite being in a construction phase [20] Strategic Outlook - The company aims for a revenue growth target of 10-15% for the full year 2025 [33] - The company emphasizes the importance of health demand and technological innovation in driving industry growth [33]

Core Viewpoint - 康龙化成 has shown strong growth in new orders and continues to enhance its global presence, leading to a positive outlook for the company [1][2]. Financial Performance - In Q1 2025, 康龙化成 achieved revenue of 30.99 billion yuan, a year-on-year increase of 16.03% - The net profit attributable to shareholders was 3.06 billion yuan, up 32.54% year-on-year, while the net profit excluding non-recurring items was 2.92 billion yuan, reflecting a 56.08% increase year-on-year [2]. - The gross margin for Q1 2025 was 66.34%, showing a year-on-year decrease of 1.01 percentage points but a quarter-on-quarter increase of 1.51 percentage points [2]. Business Segments - New orders increased by over 10% year-on-year, with laboratory services and CMC (small molecule CDMO) services both seeing significant growth [3]. - Revenue by segment includes: - Laboratory services: 18.57 billion yuan, up 15.74% year-on-year - CMC (small molecule CDMO) services: 6.93 billion yuan, up 19.05% year-on-year - Clinical research services: 4.47 billion yuan, up 14.25% year-on-year - Large molecule and cell & gene therapy services: 9.87 billion yuan, up 7.94% year-on-year [3]. Investment Outlook - The company is expected to generate revenues of 137.15 billion yuan, 155.39 billion yuan, and 173.88 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.7%, 13.3%, and 11.9% [4]. - The net profit forecasts for the same years are 17.56 billion yuan, 21.77 billion yuan, and 24.71 billion yuan, with corresponding price-to-earnings ratios of 24, 19, and 17 [4].

Core Viewpoint - The company reported a slight revenue beat in Q1 2025, with adjusted Non-IFRS net profit slightly below expectations, primarily due to higher-than-expected losses from non-operating items [1] Revenue Performance - Q1 2025 revenue reached RMB 3.099 billion, representing a 16% year-over-year increase but a 10.4% quarter-over-quarter decline, slightly above expectations [1] - Laboratory services and clinical research services outperformed expectations, contributing to revenue growth [1][2] Segment Analysis - Laboratory services revenue grew by 15.7% YoY and 1.6% QoQ, with gross margin slightly improving by 1.4 percentage points YoY and 0.2 percentage points QoQ [2] - CMC services revenue increased by 19.1% YoY but decreased by 31.5% QoQ, with a gross margin improvement of 2.5 percentage points YoY [2] - Clinical research services revenue rose by 14.2% YoY and fell by 14% QoQ, with gross margin also improving by 2.5 percentage points YoY [2] - CGT revenue grew by 7.9% YoY and 2.2% QoQ, although gross margin declined significantly by 30.3 percentage points YoY due to increased operational and depreciation costs [2] Order Growth - Overall new orders in Q1 2025 achieved a growth rate of over 10% YoY, with CMC's backlog orders growing by over 20% YoY [3] - Management maintains a revenue guidance of 10%-15% growth for the full year 2025, despite a slowdown in new order growth compared to previous quarters [3] External Factors - The impact of tariffs on the company is limited, with minimal reliance on U.S. sourced materials, and the company is well-prepared with sufficient inventory [4] - The recovery of overseas biopharmaceutical financing remains slow, with only signs of moderate recovery in VC financing [4] Investment Rating - The company maintains a "Buy" rating, with target prices set at HKD 20 for Hong Kong shares and RMB 32 for A-shares, reflecting a premium of 80% for A-shares compared to Hong Kong shares [5]